March 2016 - Bionest

31

Mar 2016

Bionest

“Beyond the Pill,” Part One: Value-Added Services Increasingly Needed Due to Changing Nature of Therapies

The notion of patient-centricity has gained increasing attention from drug developers and others in recent years, mostly in the area of chronic diseases and those requiring complex therapies. But value-added services, which go beyond simple initiatives addressed to patient compliance and access to therapy, are also gaining increasing attention from a variety of other audiences,...

23

Mar 2016

Bionest

Launch or License: Some Points to Consider, When You’re Considering Your First European Launch

For many young biotech and pharma companies, the decision about how to take their first drug to Europe has been simple: just license the European marketing rights to a company that already is well established there, and collect milestone payments and a stream of royalties. For an inexperienced company, dealing with the European regulatory and...

16

Mar 2016

Bionest

Making a “Moonshot” Against Cancer

President Obama, in his 2016 State of the Union Address, called on Vice President Biden to lead a new national “Moonshot” to “eliminate cancer as we know it.” The White House has since announced a billion dollar initiative — inspired by recent successes in the areas of cancer immunotherapy and multi-drug combinations — to jump-start this...

8

Mar 2016

Bionest

Personalized Cancer Therapies: Time to Take Lessons from “Orphan Drugs”

We recently wrote about rare disease drug development and commercialization, and why such franchises succeed better within small companies or perhaps as stand-alone, independently operating units of larger firms. When the patient population targeted by a particular therapy is small, success depends on a highly patient-centric approach to both drug development and commercialization. One must...

1

Mar 2016

Bionest

Trends to Watch in 2016 – Part 2

We started the year off in January by reviewing three of the major trends of 2015 and reflecting on where we saw events headed in 2016. In part 2 of this post, which follows yesterday’s celebration of Rare Disease Day, we’d like to discuss two further areas where we expect to see increasing focus...